Asterias Biotherapeutics Inc (NYSE:AST) has received a consensus broker rating score of 1.25 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and three have assigned a strong buy rating to the company. Asterias Biotherapeutics’ rating score has declined by 4.2% from 90 days ago as a result of various analysts’ upgrades and downgrades.

Analysts have set a 12-month consensus target price of $8.88 for the company and are anticipating that the company will post ($0.18) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Asterias Biotherapeutics an industry rank of 114 out of 265 based on the ratings given to related companies.

Several equities research analysts recently commented on the stock. Zacks Investment Research downgraded shares of Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. HC Wainwright set a $12.00 price objective on shares of Asterias Biotherapeutics and gave the company a “buy” rating in a research note on Tuesday, July 11th. Finally, Laidlaw initiated coverage on shares of Asterias Biotherapeutics in a research note on Tuesday, April 4th. They issued a “buy” rating and a $12.00 price objective on the stock.

ILLEGAL ACTIVITY NOTICE: “Analysts Expect Asterias Biotherapeutics Inc (AST) to Post ($0.18) Earnings Per Share” was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at

Asterias Biotherapeutics (NYSE:AST) traded down 2.86% during mid-day trading on Tuesday, reaching $3.40. 83,776 shares of the company’s stock traded hands. The company has a 50-day moving average of $3.34 and a 200-day moving average of $3.68. The company’s market capitalization is $167.49 million. Asterias Biotherapeutics has a 52-week low of $2.54 and a 52-week high of $5.80.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Get a free copy of the Zacks research report on Asterias Biotherapeutics (AST)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with's FREE daily email newsletter.